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A B S T R A C T
Allogeneic hematopoietic cell transplant (HCT) remains the only curative therapy for many hematologic ma-
lignancies but it is limited by high nonrelapse mortality (NRM), primarily from unpredictable control of graft-
versus-host disease (GVHD). Recently, post-transplant cyclophosphamide demonstrated improved GVHD control
in allogeneic bone marrow HCT. Here we explore cyclophosphamide in allogeneic peripheral blood stem cell
transplantation (alloPBSCT). Patients with high-risk hematologic malignancies received alloPBSCT from HLA-
matched unrelated/related donors. GVHD prophylaxis included combination post-HCT cyclophosphamide 50mg/
kg (days +3 and +4) and tacrolimus/mofetil mycophenolate (T/MMF) (day +5 forward). The primary objective
was the cumulative incidence of acute and chronic GVHD. Between March 2011 and May 2015, 35 consecu-
tive patients received the proposed regimen. MMF was stopped in all patients at day +28; the median
discontinuation of tacrolimus was day +113. Acute and chronic GVHD cumulative incidences were 17% and
7%, respectively, with no grade IV GVHD events, only 2 patients requiring chronic GVHD immunosuppres-
sion control, and no deaths from GVHD. Two-year NRM, overall survival, event-free survival, and chronic GVHD
event-free survival rates were 3%, 77%, 54%, and 49%, respectively. The graft-versus-tumor effect was main-
tained as 5 of 15 patients (33%) who received HCTwith evidence of disease experienced further disease response.
A post-transplant cyclophosphamide + T/MMF combination strategy effectively prevented acute and chronic
GVHD after alloPBSCT from HLA-matched donors and achieved an unprecedented low NRM without losing
efficacy in disease control or impaired development of the graft-versus-tumor effect. This trial is registered
at clinicaltrials.gov as NCT02300571.
© 2017 American Society for Blood and Marrow Transplantation.
INTRODUCTION
Allogeneic hematopoietic cell transplant (HCT) remains the
only curative therapy for many hematologic malignancies
[1-3]. However, broad application of the procedure has been
limited by the difficult control of graft-versus-host disease
(GVHD), the principal complication and cause of mortality
in allogeneic HCT [1,2]. The GVHD prophylaxis used most
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commonly in HCT is a calcineurin inhibitor combined with
a short course of methotrexate, which, in an unrelated donor
setting, is often supplemented by antithymocyte globulin
(ATG). Even so, 30% to 80% of allogeneic HCT patients will
develop GVHD [4-8], suggesting that development of strat-
egies to control this potentially fatal complication is key to
broadening its clinical applicability.
Cyclophosphamide given post-HCT is a novel and prom-
ising approach [9-11] that can be safely administered in high
doses, even after allogeneic HCT, without hematopoietic stem
cell toxicity. Therefore, it may be possible to exploit it to target
early-proliferating alloreactive T cells involved in GVHD onset
[10,11]. Post-transplant cyclophosphamide (PTCy) has already
been proven safe and active in both haploidentical and un-
related bonemarrow allografts [12-16]. On the contrary, PTCy
has seldom been administered in the HLA-matched alloge-
neic peripheral blood stem cell transplant (alloPBSCT) setting,
despite the use of this stem cell source in more than 75% of
HCTs from unrelated adult donors [17-23]. This study ex-
plored the performance of PTCy infusion, measured by
transplantmorbidity and outcome, when added to tacrolimus/
mofetil mycophenolate (T/MMF) as GVHD prophylaxis
regimen in alloPBSCT.
METHODS
All patients underwent HCT from PBSCs and were matched for HLA-A,
-B, -C, -DRB1, and -DQB1 alleles to either related or unrelated donors. The
following were deemed acceptable levels of recipient–donor mismatch:
an allele match for HLA-A, -B, -C, -DRB1, and -DQB1; a single allele disparity
for HLA-A, -B, -C, -DRB1 or -DQB1; two allele disparities for HLA-A, -B, or
-C; a single allele disparity for HLA-DRB1; and a single antigen plus single allele
disparity for HLA-A, -B, or -C. The criteria for clinical eligibility included age
≤ 70 years, first remission at high risk of relapse, or second remission ob-
tained after relapse or refractory hematologic malignancy. The principal
exclusion criteria were refractory central nervous system disease, active in-
fection, pregnancy, HIV-positive serology, or serious organ dysfunction (left
ventricular ejection fraction < 45% or pulmonary forced vital capacity < 50%
of predicted). All patients signed informed consent before study entry.
The study was approved by local Institutional Review Board and Ethics
Committee. The trial is registered at clinicatrials.gov (NCT02300571). Our
primary objective was to determine the capability of the drug combina-
tion to control GVHD both in acute (aGVHD) and chronic (cGVHD)
manifestations based on their cumulative incidences, assuming an ex-
pected rate of aGVHD around 80% and cGVHD around 35% [8]. Secondary
objectives were measures of nonrelapse mortality (NRM), infections, overall
survival (OS), event-free survival (EFS), cGVHD EFS, and relapse rate. aGVHD
was diagnosed based on standard criteria, whereas for cGVHD we applied
both traditional and National Institutes of Health (NIH) criteria (defined as
requiring systemic immunosuppressive treatment) [24-26]. Given the het-
erogeneity of patients, we also assessed disease risk index by the refined
criteria, which takes into account disease status, stage and cytogenetics [27].
Conditioning Regimen, Post-Graft Immunosuppression, and Supportive
Care
Conditioning regimens are reported in Table 1. Considering that the study
objective was GVHD prophylaxis, the regimens adopted were disease-
oriented. In 7 regimens cyclophosphamidewas administered also before PBSC
reinfusion on 2 consecutive days at a dose of 14.5 mg/kg (5 regimens) or
10 mg/kg (2 regimens). Immunosuppression began on days 3 and 4 after
transplant with administration of intravenous cyclophosphamide (50 mg/
kg/day). On day 5 onward, tacrolimus (.03 mg/kg in 2 daily doses; target
trough levels 5 to 10 ng/mL) andMMF (15mg/kg in 3 daily doses) were given.
Both agents were continued until day +28 when MMFwas discontinued and
day +84when a tacrolimus taper was started. Granulocyte colony-stimulating
factor (5 μg/kg/day) was started on day 5 and continued until the absolute
neutrophil count exceeded 1.0 × 109/L for 3 consecutive days.
Patients received prophylaxis for bacterial, fungal, and viral infections
as well as for Pneumocystis jiroveci [28]. Standard cytomegalic virus (CMV)
monitoring by PCR was started on day +10 and continued until day +365.
Treatment with ganciclovir or valganciclovir beganwhen the number of CMV-
DNA copies rose above 100/mL (unrelated donors) or 500/mL (related donors)
for 2 consecutive measurements or after a viral load change of >.5 log IU/
Table 1
Patient and Donor Characteristics (N = 35)
Characteristics Value
Age at transplant , yr
Median 49
Range 23-69
Sex
Male 24 (69%)
Female 11 (31%)
Disease
AML 16 (46%)
De novo AML 13 (37%)
Relapsed AML 3 (9%)
ALL 5 (14%)
De novo ALL 3 (8%)
Relapsed ALL 2 (6%)
Multiple myeloma 8 (23%)
Non-Hodgkin lymphoma 3 (8%)
MDS 2 (6%)
Hodgkin lymphoma 1 (3%)
Disease status at BMT
1† CR 15 (43%)
>1† CR 5 (14%)
Active disease 15 (43%)
CIBMTR risk group
High 20 (57%)
Intermediate 13 (37%)
Low 2 (6%)
Source of stem cell
PBSC 35 (100%)
Sex mismatch
No 22 (63%)
Yes 13 (37%)
Female into male 9 (26%)
Donor age , yr
Median 33
Range (20-68)
Source of graft
Sibling 10 (29%)
Unrelated 25 (71%)
HLA match
10/10 20 (57%)
9/10 8 (23%)
8‡/10 7 (20%)
CMV serology
CMV D−R− 1 (3%)
CMV D+R− 0 (0%)
CMV D−R+ 13 (37%)
CMV D+R+ 21 (60%)
Conditioning regimen*
Busulfan + cyclophosphamide 13 (37%)
Treosulfan + cyclophosphamide 5 (14%)
Melphalan + cyclophosphamide 4 (11.5%)
Treosulfan + cyclophosphamide +
TBI 2 Gy†
4 (11.5%)
Melphalan + cyclophosphamide +
TBI 2 Gy†
3 (8.5%)
Fludarabine + thiotepa +
cyclophosphamide
3 (8.5%)
Thiotepa + treosulfan 2 (6%)
Treosulfan + fludarabine +
cyclophosphamide
1 (3%)
Infused cell dose‡
Median CD34+ cell × 106/kg 7.4 (range, 2-15)
Median CD3+ cell × 108/kg 3.01 (range, 1.240-9.788)
Median total nucleated cells × 108/kg 12.1 (range, 6.9-16.9)
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leuke-
mia;MDS,myelodysplastic syndrome; CR, complete response; CIBMTR, Center
for International Blood and Marrow Transplant Research; TBI, total body
irradiation; CMV, cytomegalovirus; D, donor; R, recipient.
* Cyclophosphamide was given also before PBSCT at 14.5 mg/kg on 2 con-
secutive days.
† Cyclophosphamide was also given before PBSCT at 10 mg/kg on 2 con-
secutive days.
‡ CD34+ cell doses were available for all patients but CD3+ doses only for
71% of patients.
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mL in peripheral blood plasma. Epstein-Barr virus was monitored by PCR
via biweekly plasma samples [29].
Surveillance weekly blood cultures were drawn until patient dis-
charge; in cases of fever (>38.5°C), blood and urine cultures were collected
and wide-spectrum antibiotic coverage (ie, piperacillin/tazobactam 4.5 g i.v.
every 8 hours, vancomycin 500 mg i.v. every 6 hours) was undertaken until
pathogen identification or clinical control was achieved. Diagnostic and in-
vasive procedures were performed when clinically indicated. All specimens
submitted for bacterial and fungal cultures were performed according to stan-
dardmethods. Blood and platelet transfusions followed institutional protocols
[28].
Monitoring after Transplant
Neutrophil engraftment was defined as the first of 3 consecutive days
with an absolute neutrophil count > .5 × 109/L after transplant, whereas plate-
let engraftment was defined as a platelet count of 20 × 109/L with no
transfusion during the preceding 7 days. The degree of donor chimerismwas
assessed on days +30, +56, +90, +180, and +360 post-transplant on circu-
lating myeloid and CD3+ lymphocytes. Chimerismwas determined using PCR
on a panel of informative variable number tandem repeat regions, with full
chimerism defined as more than 95% donor CD3+ cells. aGVHD and cGVHD
were graded as described elsewhere [24-26].
Statistical Analysis
OS, EFS, and cGVHD-EFS were estimated using the Kaplan-Meier method
with their respective 95% confidence intervals (CIs) [30-32]. Patient death
from any cause constituted an OS event, whereas relapse or death from any
cause was characterized as an EFS event. Most broadly defined were cGVHD-
EFS events, which included any form of cGVHD (defined per NIH criteria)
[33], relapse, or death. OS, EFS, and cGVHD-EFS values were calculated from
transplant date to date of event occurrence or upon censor at final follow-
up for patients without an observed event. Discontinued immunosuppression
time was determined from the date patients ended their taper from im-
munosuppressive drugs without subsequent resumption. NRM encompassed
all deaths that occurred without evidence of relapse.
Standard methods were used to estimate rates of aGVHD and c GVHD,
relapse or progression, and NRM. Death was treated as a competing risk for
all other endpoints. Relapse was treated as a competing risk for NRM. The
study was conceived as observational aiming to understand the timing and
role of cyclophosphamide as a tool to prevent GVHD, assuming an ex-
pected rate of aGVHD around 80% and of cGVHD around 35% [8]. Categorical
variables were expressed as proportions, and continuous variables were ex-
pressed as medians within their respective ranges. All statistics were
computed using IBM SPSS Statistics (v.20; SPSS Inc., Chicago, IL) and GraphPad
Prism (v.5; GraphPad Software, Inc., La Jolla, CA).
RESULTS
Engraftment and Immune Reconstitution
Between March 2011 and April 2015 we enrolled 35 con-
secutivepatients (characteristic summary inTable 1)withhigh-
risk hematologicmalignancies treated at our center. All the 10
related donors and 10 (40%) of the unrelated oneswere 10/10
matched. Among the other 15 unrelated donors, 8 (32%) and
7 (28%) were 9/10 and 8/10 matched, respectively. Sustained
engraftment was documented in 34 of 35 patients (97%) with
median times to neutrophil and platelet recovery of 15 (range,
12 to 32) and 18 days (range, 16 to 32), respectively. Only 1
patient (3%) who developed multiresistant Pseudomonas
aeruginosa septicemia experienced primary graft failure.
Donor chimerism was >97% from day +28 and sustained
in all nonrelapsing patients. Absolute lymphocyte countsmea-
sured 400/μL (range, 40 to 1980) on day +28 after HCT, 1020/
μL (range, 50 to 4900) on day +56 after HCT, and 1300/μL
(range, 400 to 5200) on day +84 after HCT (Table 2), with CD3+
cells being 310/μL (range, 26 to 1670), 680/μL (range, 28 to
3200), and 890/μL (range, 70 to 4000), respectively.
After transplant the median time of discharge was 22 days
(range, 11-36). Three patients (9%) required readmission at
days +29, +38, and +46, respectively, because of fever (n = 2,
6%) or pneumonia (n = 1, 3%). In all cases complications were
controlled and transfer to the outpatient clinic afterwards.
Infections and Toxicity
Six of 35 patients (17%) experienced septicemia during the
engraftment phase (days 0 to 26). Staphylococcus spp. was iso-
lated in 3 of 35 patients (9%) and gram-negative bacilli
(Pseudomonas aeruginosa, Acinetobacter lwoffii, and Klebsi-
ella pneumoniae) in 3 of 35 patients (9%). Treatment with the
appropriate antibiotic therapy resulted in complete control
of all but 1 infection. Two of 35 patients (6%) colonized with
K. pneumoniae carbapenemase–producing bacteria before HCT
suffered transient aplasia after transplant. They experi-
enced fevers of unknown origin that were successfully treated
Table 2
Post-Transplant Data
Data Value
Median engraftment time
Neutrophil engraftment > .5 × 109/L 15 days (range, 12-26)
Platelet engraftment > 20 × 109/L 18 days (range, 16-60)
Peripheral blood lymphocyte count*
Median day +28, U/μL 400 (range, 40-1.980)
Median day +56, U/μL 1.020 (range, 50-4.900)
Median day +84, U/μL 1.300 (range, 400-5.200)
Median day +180, U/μL 1.900 (range, 580-4.200)
Chimerism†
Day +28 >97% of patients alive and not relapsed
Day +56 >97% of patients alive and not relapsed
Day +84 >97% of patients alive and not relapsed
CMV reactivation
Incidence 21/35 (60%)
Median day of reactivation 38 (range, 22-54)
Bloodstream infection during engraftment (days 0-26)
Incidence 6/35 (17%)
Toxicity (grades 3-4)‡
Liver enzymes elevation 5/35 (14%)
Hyperbilirubinemia 1/35 (3%)
Mucositis 7/35 (20%)
Hemorrhage§ 3/35 (9%)
Sinusoidal obstruction disease 1/35 (3%)
* Peripheral blood lymphocyte count was available on days +28, +56, and +84 for all patients.
† Chimerism on peripheral blood was available for all patients alive without disease relapse.
‡ Toxicities were graded according to standard National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0.
§ Hemorrhagic cystitis.
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with antibiotics (meropenem 2 g every 8 hours, gentamycin
80 mg every 8 hours, and tigecyline 50 mg every 12 hours),
which allowed both patients to be discharged after engraft-
ment (days +18 and +23, respectively). No patient developed
a pulmonary fungal infection during transplant or follow-up.
CMV reactivation occurred in 21 of 35 patients (60%) at
a median +38 days (range, 22 to 54). No case of primary CMV
infection was reported, and only 1 patient (3%) had late CMV
reactivation (day +232). In all CMV cases preemptive therapy
was successful. No Epstein-Barr virus–related disease was ob-
served. Hemorrhagic cystitis with BK viriuria was witnessed
in 3 of 35 patients (9%) on day +24, +41, and +46, respective-
ly. However, complete resolution of the infectionwas achieved
in all patients within 4 to 6 weeks.
Three of 35 patients (9%) were hepatitis B virus–positive
beforeHCT.Of these, 2 (67%) suffered viremia reactivation after
transplant. The first patient, who was on entecavir treatment
for a mutated hepatitis B virus form (YMDD) at the time of
transplant, experienced a viremia flare-up on day +84. Asso-
ciation therapy (entecavir/tenofovir)was initiated andprompt
control achieved. The second patient, for whom lamivudine
had been discontinued 12 months post-HCT, was diagnosed
on day +540 with hepatitis B virus–mutated hepatitis (codon
M250LM) that was successfully treated with tenofovir.
Grades 3 and 4 toxicities that occurred during the first 100
days after transplant are listed in Table 2. Grade 3 mucositis
(20%, 7/35) and liver enzyme elevation (14%, 5/35) emerged
most often. Mild sinusoidal occlusion syndrome occurred in
1 patient (3%) [34].
Immunosuppression, GVHD, and Graft-versus-Tumor
Effect
After discontinuation of MMF (day +28 for all patients) and
tacrolimus (median, +113 days; range, 49 to 276), only 2 of
21 patients (9%) alive without disease progression required
immunosuppression restart. The overall cumulative inci-
dence across all aGVHD grades was 17% (95% CI, 2% to 45%),
of which 12% were grades II to III (95% CI, 1% to 48%), and
none was grade IV. The median aGVHD onset was +75 days
(range, 22 to 98) (Figure 1A). No cases of late-onset aGVHD
were reported. Three of 35 patients (9%) who required steroid
therapy responded well, such that it was discontinued after
a median 75 days (range, 36 to 200). At 2 years the cumu-
lative incidence of NIH-defined cGHVD requiring systemic
immunosuppression was 7% (95% CI, 1% to 51%) (Figure 1B).
We also analyzed the cumulative incidence of overall
(limited + extensive) cGVHD defined by traditional criteria.
At 2 years the incidence was 11% equally due to limited (1
patient) and extensive cGVHD (2 patients). No patient died
fromGVHD. Because of the low event rate an analysis to assess
the possible role of donor source on GVHD incidence was not
conducted. After we enrolled the first 35 patients, the ob-
served activity (aGVHD, 17%; cGVHD, 7%) was much greater
than expected both in magnitude and overall duration
(P < .0001 and P = .0033, respectively).
Among the 21 of 35 patients (60%) alive without disease
progression, 5 (24%) whowere transplanted with evidence of
disease (1 acutemyeloid leukemia, 1 acute lymphoblastic leu-
kemia, 1myelodysplastic syndrome, 1multiplemyeloma, and
1 refractory follicular non-Hodgkin lymphoma) achieved and
maintained complete response after alloPBSCT.
Outcomes
Themedian follow-up period for the entire population was
20 months (range for patients without an event, 9 to 67
months). The only patient who died of NRM accounted for
the 2-year NRM cumulative incidence of 3% (95% CI, 0% to
61%) (Figure 1C). Estimated 1-year OS and EFS for all pa-
tients were 86% (95% CI, 69% to 94%) and 60% (95% CI, 42%
to 74%), respectively; at 2 years they were 77% (95% CI,
59% to 88%) and 54% (95% CI, 37% to 69%), respectively
(Figure 2A,B). The 2-year cumulative incidence of relapse
was 46% (95% CI, 28% to 62%) across all patients and 25%
(95% CI, 3% to 56%) for patients undergoing HCT in com-
plete response (Figure 2C). For the 20 of 35 patients (57%)
transplanted in complete response, only 4 (20%) relapsed: 3
Figure 1. Transplant-related complications. (A) Cumulative incidence of
aGVHD. (B) Cumulative incidence of cGVHD. (C) Cumulative incidence of
NRM.
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with acute myeloid leukemia (1 with FLT3-positive disease
on day +67, 1 with NPM1-positive form on day +162, and 1
with central nervous system extramedullary relapse on day
+706). At relapse all patients were treated with mitoxantrone,
etoposide, and cytarabine regimen followed in the first patient
by sorafenib and a second allogeneic HCT (intra–bone cord
blood transplant), in the second patient by fludarabine,
cytarabine, liposome-encapsulated-doxorubicin and granu-
locyte colony-stimulating factor and a second allogeneic HCT
(intra–bone cord blood transplant), and in the third patient
by FLAG-Myocet (2 cycles) followed by local conforma-
tional radiotherapy. Only 1 patient is still alive; the other 2
died from further relapse at days +245 and +1067, respec-
tively. The fourth patient transplanted for myelodysplastic
syndrome relapsed on day +128 and was treated with
5-azacitidine. Overall, 1- and 2-year rates of cGVHD-EFS were
54% (95% CI, 37% to 69%) and 49% (95% CI, 31% to 64%), re-
spectively (Figure 2D). All employed patients returned to work
after a median of 9 months (range, 168 to 462 days).
DISCUSSION
This study described the impact of a modified strategy to
prevent GVHD by using cyclophosphamide in the early post-
transplant days. We observed sharp reductions in aGVHD and
cGVHD to 17% and 7%, respectively. Consistently, NRM was
reduced to a mere 3%.
When allogeneic HCT was introduced into clinical prac-
tice during the early 1990s, it appeared to be a very effective
therapy for many hematologic malignancies that were
otherwise incurable [3]. However, the procedure was char-
acterized by extremely high toxicity that resulted in a 30%
to 40% mortality risk [35,36]. Over the years, deeper knowl-
edge of the HLA system and transplant immunology, better
selection and matching of donors and patients, and the
advent of new immunosuppressive and antimicrobial drugs
have led to a mortality risk reduction that is now approxi-
mately 15% to 20% [1]. Nonetheless, this rate still represents
a burden that limits extensive application of HCT. Only by con-
trolling GVHD will it be possible to reduce such toxicity to
below 5%.
As a result of the introduction of PTCy in allogeneic
HLA-matched bone marrow transplant as well as in the
haploidentical setting, considerable progress in the preven-
tion of GVHD has been made [9,12-16]. Only recently, initial
data on the impact of this regimen after alloPBSCT in HLA-
matched donors have been reported [17-19,37,38]. The first
clinical experience described the role of PTCy as sole GVHD
prophylaxis in 11 patients; the grades II to IV aGVHD inci-
dence of 45% and the NRM in up 36% of cases discouraged
further evaluation of this approach [18]. Subsequently, the
Seattle group published on 42 patients treated with PTCy to
which cyclosporine was added as GVHD prophylaxis. This pro-
phylaxis did not consider HLA-mismatched unrelated
donors—43% of our patients—and translated to a 70% inci-
dence of grade II aGVHD but without any grades III to IV; the
approach was revealed to be very active in protection toward
cGVHD and NRM, with NIH-defined cGVHD and NRM rates
of 16% and 14%, respectively [17]. Along with these studies,
Figure 2. Kaplan-Meier survival curves. (A) OS. (B) EFS. (C) Relapse incidence in all patients (solid line) and in patients who underwent BMT with complete
remission (CR) of the underlying disease (dashed line). (D) GVHD-EFS.
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Moiseev et al [37] reported on 86 patients affected by acute
leukemias treated with PTCy and T/MMF. The main focus of
the study was a retrospective comparison with an histori-
cal control group of patients treated with ATG, calcineurin
inhibitors, and methotrexate. The incidence of grades II to IV
aGVHDwas 19% and of cGVHD 16%, and the NRMwas as low
as 16%. This study, however, did not described in detail the
post-transplant clinical course in terms of immunosuppres-
sion taper, discontinuation, and number of patients requiring
to restart it.
In addition to these 3 studies aiming to better define the
ideal combination of PTCy and standard GVHD preventive
regimens after alloPBSCT, 2 more studies were reported
where PTCy was followed by an experimental GVHD
prophylaxys with sirolimus. In the first study, among the
26 patients treated aGVHD grades II to IV ranged around
45% and cGVHD was quoted at 31% with 37% and 11% of
patients still on immunosuppression at 1 and 2 years, re-
spectively, whereas NRM at 2 years was 13% [19]. In the
second study, where in unrelated patients MMF was added
to cyclophosphamide and sirolimus, aGVHD grades II to IV
was in the order of 30% to 35% and cGVHD 16% at 1 year.
NRM was 14% at 1 year, but the median follow-up reported
was 225 days, and this does not allow the drawing of any
further conclusion [38].
Given these premises, the results reported in our study
add more information to the general picture. First, PTCy after
PBSCT resulted in rapid engraftment as observed with con-
ventional GVHD prophylaxis [20,21,39]. Moreover, hematologic
recovery made the procedure very tolerable, shortened the
inpatient stay, and reduced the rate of hospital readmis-
sion. Second, the addition of T/MMF to PTCy was not
detrimental to a rapid and sustained lymphocyte recovery that
helped to contain severe infection incidence rates to that seen
in similar previous PTCy studies, as opposed to historical al-
logeneic alloPBSCT data using standard GVHD regimens
[9,12,15,18,40].
A third important finding led to another set of conclu-
sions. PTCy after PBSCT resulted in high activity in aGVHD
and cGVHD prevention. In fact, PTCy synergy with T/MMF de-
termined a lower incidence of aGVHD compared with both
conventional alloPBSCT (grades II to IV, 45% to 80%) [1,2,8,41]
and reduced-intensity regimens (42% to 64%) [42] as well as
to PTCy after allogeneic bone marrow transplantation
(alloBMT; 43% to 51%) [9,12,13]. Furthermore, despite PBSC
use, this strategy maintained a robust protection against
cGVHD that, with conventional prophylaxis, may be as high
as 48% [20]. This high control rate allowed lower steroid use
comparedwith conventional calcineurin inhibitor–based strat-
egies and earlier discontinuation of immunosuppressive
therapy, staving off the need for its later reintroduction in
most patients [7,43,44]. These data distinguish our study
regimen from the previous ones of PTCy in either alloBMT
or alloPBSCT [9,12,13,17-19]. In the BMT setting, at least 43%
to 51% of patients were required to restart some form of im-
munosuppression after transplant; in the PBSCT setting,
the Seattle group described that, regardless of high-grade
matching requested in unrelated transplants, at 1 year 30%
of the 33 patients still alive were still on immunosuppres-
sion and that, among those diagnosed with cGVHD, 6 of 7
(86%) were still on immunosuppression at the time of the
report [9,17]. Our finding, if confirmed in a larger patient
cohort, is extremely appealing because a post-allogeneic HCT
state that requires no further immunosuppression may be a
platform to develop future post-transplant cellular thera-
pies that safely and specifically act on minimal residual
disease.
Two outcome indicators demonstrated the direct conse-
quence of GVHD control. One is the NRM of 3% (after
conventional alloPBSCT and alloBMT with PTCy, NRM ranged
between 21% to 30% and 15%, respectively) [9,12,20]. Notably,
a 3% treatment-related mortality compares closely with what
observed in the autologous setting [45]. The second indica-
tor is the cGVHD-EFS that nearly overlapped EFS, thus
confirming the long-term tolerability of this regimen.
Finally, “double” post-transplant immunosuppression
might raise concerns about relapse incidence and the capa-
bility of generating an effective graft-versus-tumor (GVT)
effect. In regard to the first point, although in our series relapse
in patients transplanted not in complete response also remains
a relevant issue, we reported an EFS and OS comparable with
those described after conventional alloPBSC or alloBMT with
PTCy, suggesting no impact of our strategy on the post-
transplant outcomes [9,17,19,20]. The fast immunosuppression
taper and the reduced need afterward of a new immuno-
suppressive treatment that we described, however, may lay
the ground for future studies aiming to explore, in patients
transplanted not in complete response, an early introduc-
tion of post-transplant cell therapies. In regard to the second
point, GVT, although we did not give formal immune bio-
logic evidence, we reported that 5 of 15 patients (33%) in
partial response achieved and maintained complete re-
sponse after transplant as a consequence of the allogeneic-
based therapy. These data might support the intriguing
concept that GVT is not sustained by early-proliferating donor
T cells (targeted by early-phase immunosuppressive drugs)
but rather by a different T cell population that needs time to
develop and expand [46].
We acknowledge our data mandate further confirma-
tion because are limited by the observational nature, the
relatively small sample size (that is, however, very similar to
other PTCy studies), heterogeneity of hematologic malignan-
cies treated, and, consequently, conditioning regimens used
[17,19]. Notwithstanding, these weaknesses are partly miti-
gated by the fact that the primary objective of the trial was
GVHD control, and a valid GVHD prophylaxis should bewidely
reproducible in most transplant centers and should adapt to
any disease and to specific conditioning regimens. For these
reasons, despite the above-mentioned limitations, our results
set the basis for the design of future clinical trials. This state-
ment becomes more relevant in light of recent results
achieved with ATG in related alloPBSCT [47]. In this setting,
a large phase III trial showed that ATG inclusion produced
both a clear reduction of cGVHD incidence and an improve-
ment in cGVHD-EFS. However, at 2 years 25% of patients were
suffering from cGVHD. Acknowledging the nonrandomized
nature of our results, we did not observe any cGVHD late
relapse both in related and unrelated donors, suggesting these
2 strategies should be compared in the near future; as
also suggested by another recent large retrospective study
[37].
In conclusion, the present study provides evidence that
PTCy in association with T/MMF after alloPBSCT can sub-
stantially decrease both aGVHD and cGVHD, reducing NRM
to less than 5%. If these results are confirmed in a larger clin-
ical trial, then the application of allogeneic HCT might be
broadened, and this strategy could be transformed into a safe
immunologic platform for development of future cellular
therapies aimed at generating a more effective and long-
lasting GVT effect [48-50].
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